Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100963 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Natalia Fernández Núñez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Lucus Augusti, Lugo, Spain. Electronic address: fernandeznunez.ntalia@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Docetaxel, Indoles, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Boehringer Ingelheim España SA Malgrat de Mar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Patients with advanced non-small cell lung cancer (NSCLC) who progress after chemotherapy and immune checkpoint inhibitors (ICIs) need effective second-line treatments. The combination of nintedanib and docetaxel has shown promise, particularly post-ICI progression. This study evaluates the efficacy, safety, and prognostic factors of this regimen in a cohort from the Galician Lung Cancer Group. MATERIALS AND METHODS: This observational, multicenter, retrospective study included 45 patients with advanced or metastatic NSCLC who had progressed after at least one line of immunotherapy and chemotherapy. All received nintedanib and docetaxel. Overall survival (OS), progression-free survival (PFS), and adverse events were analyzed using descriptive and inferential statistics, including Kaplan-Meier survival analysis. RESULTS: The median age was 61 years, with 69 % male. The disease control rate was 59.1 % in the second line and 37 % in the third line. Median OS was 20 months (95 % CI: 15-25). Subgroup analysis showed that elevated LDH levels (>246 UI/L) were associated with improved OS (HR = 0.38; 95 % CI: 0.18-0.77). High PD-L1 expression (≥50 %) was linked to longer survival (HR: 0.48; 95 % CI: 0.18- 1.25), while active smoking correlated with worse outcomes (HR: 1.06; 95 % CI: 0.40-2.78). Grade ≥3 toxicities included diarrhea (6.7 %), hematologic toxicity (13.3 %), hepatic toxicity (4.5 %), and vomiting (2.2 %). CONCLUSIONS: Nintedanib and docetaxel demonstrated meaningful efficacy and an acceptable safety profile in advanced NSCLC after immunotherapy and chemotherapy failure. LDH, PD-L1, and smoking status emerged as important prognostic factors, warranting further prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Lucus Augusti, Lugo, Spain. Electronic address: fernandeznunez.ntalia@gmail.com.
- Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.
- Servicio de Oncoloxía Médica & Grupo de Oncoloxía Médica Traslacional Hospital Clínico Universitario & Instituto de Investigación Sanitaria de Santiago de Compostela, A Coruña, Spain.
- Servicio de Oncología Médica C.H.U.Ferrol, Ferrol, A Coruña, Spain.
- Complejo Hospitalario universitario de Ourense, Ourense, Spain.
- Hospital universitario de A Coruña, Spain.
Förderung
- Boehringer Ingelheim
- Boehringer Ingelheim España SA Malgrat de Mar
Zitieren
APA
Fernández Núñez, N., Lázaro Quintela, M., García González, J., Afonso Afonso, F. J., Areses Manrique, M. C., Azpitarte Raposeiras, C., Mosquera Martinez, J., & Santomé Couto, L. (2025). Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100963
Vancouver
Fernández Núñez N, Lázaro Quintela M, García González J, Afonso Afonso FJ, Areses Manrique MC, Azpitarte Raposeiras C, et al. Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100963
BibTeX
@article{FernndezNez2025,
author = {Fernández Núñez, Natalia and Lázaro Quintela, Martín and García González, Jorge and Afonso Afonso, Francisco Javier and Areses Manrique, María Carmen and Azpitarte Raposeiras, Cristina and Mosquera Martinez, Joaquin and Santomé Couto, Lucia},
title = {Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100963}
}
EUVIMED